drug
enasidenib mesylate
Marketedupdated 3mo agoby Bristol-Myers Squibb Co
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying enasidenib mesylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 21, 2030
~3.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Sep 16, 2034compositionUS 9732062
- Sep 16, 2034compositionUS 9732062
- Aug 1, 2034compositionUS 10093654
- Aug 1, 2034compositionUS 10093654
- Aug 1, 2034compositionUS 9738625
- Aug 1, 2034compositionUS 9738625
- Jan 7, 2033formulationUS 10294215
- Jan 7, 2033formulationUS 10294215
- Jan 7, 2033compositionUS 9512107
- Jan 7, 2033compositionUS 9512107
- Jun 21, 2030method-of-use (U-2087)US 106101253.8y
- Jun 21, 2030method-of-use (U-2087)US 106101253.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that